This page contains a Flash digital edition of a book.
Available treatments: PAH


regimens are still associated with limiting symptoms and poor outcomes. There is accumulating evidence that the combination of therapies which target distinct pathobiologic mechanisms is beneficial, and recent studies suggest that an aggressive upfront combination approach may be the best way to improve symptoms and delay progression of this devastating disease. l


References 1. Galiè N et al. Updated treatment algorithm of pulmonary arterial hypertension. JACC 2013;62(25)Suppl:D60–72.


2. Sitbon O, Morrell NW. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21(126):321–7.


3. US Food and Drug Administration. www. accessdata.fda.gov/scripts/cder/drugsatfda/ (accessed 5 August 2014).


4. European Medicines Agency. www.ema.europa. eu/ema/ (accessed 5 August 2014).


5. Letairis® Prescribing Information, 2014. 6. Galiè N et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010–19.


7. Badesch DB et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30(2):93–9.


8. Rubin LJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896–903.


9. Galiè N et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093–100.


10. Pulido T et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.


11. Galiè N et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.


12. Rubin LJ et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011;140(5):1274–83.


13. Galiè N et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894–903.


14. Oudiz RJ et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol. 2012;60(8):768–74.


15. Ghofrani HA et al. Riociguat for the treatment of pulmonary arterial hypertension.N Engl J Med 2013;369(4):330–40.


22


16. Flolan® Prescribing Information, 2011. 17. Barst RJ et al. A comparison of continuous


www.hospitalpharmacyeurope.com


intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–302.


18. Simmoneau G et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800–4.


19. Jing ZC et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127(5):624–33.


20. McLaughlin VV et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915–22.


21. Olschewski H et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002 Aug 1;347(5):322–9.


22. Galiè N et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double- blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496–502.


23. Barst RJ et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:219–25.


24. Actelion. www.actelion.com/en/investors/ media-releases/index.page?newsId=1793163 (accessed 5 August 2014).


25. www.gilead.com/news/press-releases/2014/9/ firstline-combination-of-ambrisentan-and- tadalafil-reduces-risk-of-clinical-failure- compared-to-monotherapy-in-pulmonary- arterial-hypertension-outcomes-study.


26. McLaughlin VV et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174(11):1257–63.


27. Hoeper MM et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary


arterial hypertension. Eur Respir J 2006;28(4): 691–4.


28. Humbert M et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353–9.


29. Simonneau G et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149(8):521–30.


30. Simonneau G et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014;33(7):689–97.


31. Tapson VF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142(6):1383–90.


32. Tapson VF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013 Sep;144(3):952–8.


33. Galiè N et al. A placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). Am J Resp Crit Care Med 2013;187:A3530.


34. Vachiery J-L, Simmonneau, G. Management of severe pulmonary arterial hypertension. Eur Respir Rev 2010;19(118):279–87.


35. Hoeper MM et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26(5):858–63.


36. Rubin LJ et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Int Med 1990;112:485–91.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44